Retinal vein occlusion (RVO) is considered the second vascular disorder of the retina after diabetic retinopathy. Patients with RVO are at risk of the development of macular edema. Different treatment modalities for macular edema include LASER therapy, antivascular endothelial growth factor (VEGF), and triamcinolone.

Aim To detect the efficacy of formulated Triamcinolone Acetonide(TA) injection in the posterior subtenon space to manage macular edema secondary to non-ischemic RVOs, either central or branch.

Inclusion Criteria:

• Diminution of vision due to macular edema secondary to non-ischemic retinal vein occlusions, either central or branch
• CMT ≥ 250 µ,
• Willing to participate in the study.

Exclusion Criteria:

• Unwilling to participate in the study
• Ischemic RVO
• previous laser treatment
• Glaucoma, macular ischemia, cataract, vitreous hemorrhage, and neovascularization of the iris
• patients with previous anti VEGFs or steroid injections or any eye surgery three months before the inclusion
• Cardiac co-morbidities result in significant hemodynamic changes
• Respiratory diseases need treatment with antibiotics
• Suffering from other chronic diseases as diabetes
• Patient with allergy from triamcinolone acetonide.